Pharmaceutical Business review

Bedford Laboratories launches irinotecan HCl injection

Irinotecan is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. This product is available for immediate shipment nationwide.

Bedford Laboratories will supply irinotecan HCl injection as a sterile aqueous solution available in two different dosages including 40mg/2ml single dose amber vials individually boxed and 100mg/5ml single dose amber vials individually boxed.